3 active not recruiting, 3 recruiting, 2 not yet recruiting, 1 available. 6 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 2, Not yet recruiting 2, Recruiting 2 |
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Orca Biosystems, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | University of California, Davis | 20 | 2026-09-01 | 2026-08-12 |
| Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Orca-T - Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 2 | Recruiting | Orca Biosystems, Inc. | 80 | 2025-12-09 | 2026-07-07 |
| A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis Orca-Q, myeloablative regimen - Primary Progressive Multiple Sclerosis, Multiple Sclerosis | Phase 1 | Not yet recruiting | Stanford University | 10 | 2025-03-01 | 2025-03-28 |
| Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Orca-Q - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Florida | 40 | 2022-08-16 | 2026-09-01 |
| Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Orca-T, Standard-of-Care - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 3 | Active not recruiting | Orca Biosystems, Inc. | 187 | 2022-06-21 | 2026-03-04 |
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan - Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies | Phase 1 | Active not recruiting | Stanford University | 66 | 2021-09-07 | 2026-05-12 |
| Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Orca-T - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 | Active not recruiting | Orca Biosystems, Inc. | 155 | 2019-11-21 | 2026-08-14 |
| A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies OrcaGraft (Orca-Q) - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Recruiting | Orca Biosystems, Inc. | 300 | 2019-04-08 | 2026-09-29 |
| Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies Orca-T - Hematologic Malignancies, Acute Myeloid Leukemia | Available | Orca Biosystems, Inc. | 2026-09-21 |
Leukemia, Myeloid, Acute (6) · Myelodysplastic Syndromes (6) · Leukemia, Biphenotypic, Acute (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Hematologic Neoplasms (3) · Disease (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Acute Disease (1) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Bone Marrow Diseases (1) · Disease Attributes (1) · Graft vs Host Disease (1) · Hematologic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1)
Thiotepa (3) · fludarabine (3) · Busulfan (2) · Granulocyte Colony-Stimulating Factor (2) · Alkylating Agents (1) · Cyclophosphamide (1) · Filgrastim (1) · Melphalan (1) · Mycophenolic Acid (1) · Sirolimus (1) · Standard of Care (1) · Tacrolimus (1) · fludarabine phosphate (1) · plerixafor (1) · ruxolitinib (1)
United States (8)
Everett Meyer, MD,PhD (1) · James S McClellan, MD, PhD (1) · Jordan Milner, MD (1) · Mehrdad Abedi (1)
PMID 39170618, PMID 41385341, PMID 42806776
P30CA093373 (1)